Viral diseases

Todos Medical to Launch EUA Authorized cPass SARS-CoV-2 Neutralizing Antibody Kit Through Agreement with Fosun Pharma

Retrieved on: 
Monday, July 19, 2021
Medical specialties, Branches of biology, Medicine, Antibodies, Neutralizing antibody, Viral diseases, Development of COVID-19 tests, COVID-19 vaccines, DiaSorin

The Company is currently automating the EUA cPass test at itsCLIA/CAP laboratory, Provista Diagnostics (Provista), to add high-capacity neutralizing antibody testing to its test menu, and is ramping up its sales and marketing infrastructure.

Key Points: 
  • The Company is currently automating the EUA cPass test at itsCLIA/CAP laboratory, Provista Diagnostics (Provista), to add high-capacity neutralizing antibody testing to its test menu, and is ramping up its sales and marketing infrastructure.
  • Todos will also make cPass available for client labs to run on their automated equipment.
  • This test has been authorized by FDA under an EUA for use by authorized laboratories.
  • This test has been authorized only for the presence of total neutralizing antibodies against SARS-CoV-2, not for any other viruses or pathogens.

Human Cytomegalovirus Envelope Glycoprotein B (gB) Drugs Development Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 14, 2021
Infectious diseases, Pharmaceutical, Health, Betaherpesvirinae, Viral diseases, Virology, Medical specialties, Microbiology, Viral structural proteins, Viral envelope, env, Human betaherpesvirus 5, Cytomegalovirus

The "Human Cytomegalovirus Envelope Glycoprotein B (gB) - Drugs In Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Human Cytomegalovirus Envelope Glycoprotein B (gB) - Drugs In Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) pipeline Target constitutes close to 10 molecules.
  • The latest report Human Cytomegalovirus Envelope Glycoprotein B - Drugs In Development, 2021, outlays comprehensive information on the Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • It also reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics development with respective active and dormant or discontinued projects.

GeoVax Announces Issuance of Hepatitis B Vaccine Patent

Retrieved on: 
Wednesday, July 7, 2021
Medical specialties, Health, Clinical medicine, Infectious causes of cancer, Healthcare-associated infections, Viral diseases, Epidemiology, Virus, Zoonoses, Hepatitis, Patent application, Viral hepatitis

11,052,148, entitled Composition and Methods of Generating an Immune Response to Hepatitis B Virus.

Key Points: 
  • 11,052,148, entitled Composition and Methods of Generating an Immune Response to Hepatitis B Virus.
  • The abstract contained in the Companys patent application describes the invention as follows: The compositions and methods are described for generating an immune response to a hepatitis B virus.
  • The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat an infection caused by hepatitis B virus.
  • We are pleased now to have been notified of the formal patent issuance.

SIGA Supplies TPOXX® (Tecovirimat) as Compassionate Treatment for Monkeypox Case in the United Kingdom

Retrieved on: 
Wednesday, June 30, 2021
Chordopoxvirinae, Poxviruses, Medical specialties, Virology, Viral diseases, Monkeypox, Smallpox, Tecovirimat, Poxviridae, Pox, Infection, Orthopoxvirus

TPOXX, which is approved in the United States for the treatment of smallpox, was delivered to Liverpool for compassionate treatment for a patient confirmed to be infected with monkeypox.

Key Points: 
  • TPOXX, which is approved in the United States for the treatment of smallpox, was delivered to Liverpool for compassionate treatment for a patient confirmed to be infected with monkeypox.
  • Monkeypox is a contagious disease caused by infection with monkeypox virus, a virus closely related to variola virus, which causes smallpox.
  • Monkeypox is characterized by severe flu-like symptoms and a rash of pus-filled pocks that may cover the whole body.
  • On July 2018, the U.S. Food and Drug Administration (FDA) approved the oral formulation of TPOXX (tecovirimat) for the treatment of smallpox.

Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021

Retrieved on: 
Wednesday, June 23, 2021
General Health, Science, Health, Research, Medical specialties, Infectious diseases, Clinical medicine, Infectious causes of cancer, Viral diseases, Hepadnaviridae, Hepatitis B, Hepatitis, the BRII-179 (VBI-2601) Phase 1b/2a Study, Hepatitis B, BRII-179 (VBI-2601), VBI Vaccines, THE BRII-179 (VBI-2601) PHASE 1B/2A STUDY, HEPATITIS B, BRII-179 (VBI-2601), VBI VACCINES

Brii Biosciences (Brii Bio) and VBI Vaccines Inc. (NASDAQ: VBIV) (VBI), today announced final results from a Phase 1b/2a study on BRII-179 (VBI-2601), a novel recombinant, protein-based immunotherapeutic candidate, in patients with chronic hepatitis B virus (HBV) infection.

Key Points: 
  • Brii Biosciences (Brii Bio) and VBI Vaccines Inc. (NASDAQ: VBIV) (VBI), today announced final results from a Phase 1b/2a study on BRII-179 (VBI-2601), a novel recombinant, protein-based immunotherapeutic candidate, in patients with chronic hepatitis B virus (HBV) infection.
  • A Phase 2 combination study of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) aimed at developing a functional cure for chronic HBV began in April 2021.
  • Two additional Phase 2 studies of BRII-835 (VIR-2218) in combination with other agents are also expected to start in 2021.
  • VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM).

Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021

Retrieved on: 
Wednesday, June 23, 2021
Research, Infectious diseases, FDA, Clinical trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Medical specialties, Infectious diseases, Clinical medicine, Infectious causes of cancer, Viral diseases, Hepadnaviridae, Hepatitis B, Hepatitis, the BRII-179 (VBI-2601) Phase 1b/2a Study, Hepatitis B, BRII-179 (VBI-2601), VBI Vaccines, THE BRII-179 (VBI-2601) PHASE 1B/2A STUDY, HEPATITIS B, BRII-179 (VBI-2601), VBI VACCINES

Brii Biosciences (Brii Bio) and VBI Vaccines Inc. (NASDAQ: VBIV) (VBI), today announced final results from a Phase 1b/2a study on BRII-179 (VBI-2601), a novel recombinant, protein-based immunotherapeutic candidate, in patients with chronic hepatitis B virus (HBV) infection.

Key Points: 
  • Brii Biosciences (Brii Bio) and VBI Vaccines Inc. (NASDAQ: VBIV) (VBI), today announced final results from a Phase 1b/2a study on BRII-179 (VBI-2601), a novel recombinant, protein-based immunotherapeutic candidate, in patients with chronic hepatitis B virus (HBV) infection.
  • A Phase 2 combination study of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) aimed at developing a functional cure for chronic HBV began in April 2021.
  • Two additional Phase 2 studies of BRII-835 (VIR-2218) in combination with other agents are also expected to start in 2021.
  • VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM).

Enanta Pharmaceuticals Presents New Data for EDP-721, an Oral Hepatitis B Virus RNA Destabilizer, at the European Association for the Study of the Liver (EASL) International Liver Congress™

Retrieved on: 
Wednesday, June 23, 2021
Health, Infectious diseases, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Medical specialties, Clinical medicine, Health, Infectious causes of cancer, Viral diseases, Healthcare-associated infections, Hepadnaviridae, Hepatitis B virus, HBsAg, Hepatitis B, Hepatitis, Viral hepatitis, Hepatitis B Virus, Enanta, HEPATITIS B VIRUS, ENANTA

The data demonstrate potent, selective and pangenotypic inhibition of HBV surface antigen (HBsAg), with up to a 3-log drop in the AAV-HBV mouse model.

Key Points: 
  • The data demonstrate potent, selective and pangenotypic inhibition of HBV surface antigen (HBsAg), with up to a 3-log drop in the AAV-HBV mouse model.
  • The research on EDP-721 was presented in a poster titled Discovery and Characterization of EDP-721, a Novel Hepatitis B Virus RNA Destabilizer, during the EASL International Liver Congress 2021.
  • Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease.
  • Enantas research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie.

Hologic Receives European CE Mark for Molecular Assay to Quantify Human Cytomegalovirus

Retrieved on: 
Wednesday, June 23, 2021
General Health, Surgery, Other Health, Health, Oncology, Virology, Medical specialties, Betaherpesvirinae, Viral diseases, Microbiology, Human betaherpesvirus 5, Cytomegalovirus, Virus latency, Hologic

Hologic, Inc. (Nasdaq: HOLX) has received CE mark for its new Aptima CMV Quant assay in Europe, the Company announced today.

Key Points: 
  • Hologic, Inc. (Nasdaq: HOLX) has received CE mark for its new Aptima CMV Quant assay in Europe, the Company announced today.
  • This assay, which quantifies the viral load of human cytomegalovirus (CMV), is intended for use to aid in the diagnosis and management of solid-organ transplant patients and hematopoietic stem cell transplant patients.
  • Hologic, The Science of Sure, Aptima, and Panther are registered trademarks of Hologic, Inc. in the United States and/or other countries.
  • The immunology of human cytomegalovirus latency: could latent infection be cleared by novel immunotherapeutic strategies Cell and Mol Immunol.

VBI Vaccines to Present at Upcoming Scientific Conferences

Retrieved on: 
Thursday, June 17, 2021
Research, Infectious diseases, FDA, Clinical trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Medical specialties, Clinical medicine, Health, Vaccines, Infectious causes of cancer, Viral diseases, Virology, Animal virology, Hepatitis, Vaccine, Virus, Coronavirus, Hepatitis B, VBI’s 3-Antigen Hepatitis B Vaccine, VBI Vaccines Inc., HEPATITIS B, VBI’S 3-ANTIGEN HEPATITIS B VACCINE, VBI VACCINES INC.

Hepatitis B is one of the worlds most significant infectious disease threats with more than 290 million people infected globally.

Key Points: 
  • Hepatitis B is one of the worlds most significant infectious disease threats with more than 290 million people infected globally.
  • To learn more about VBIs 3-Antigen Hepatitis B vaccine candidate visit: https://www.vbivaccines.com/sci-b-vac/
    VBI Vaccines Inc. (VBI) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease.
  • VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM).
  • VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.

Science Translational Medicine Publication: Innovative Molecules´ Drug Candidate Affects Recurrent Herpes Simplex Virus Infections

Retrieved on: 
Wednesday, June 16, 2021
Medical specialties, Sexually transmitted diseases and infections, Virology, Herpes, Clinical medicine, Viral diseases, Herpes simplex virus, Herpes simplex, Herpes labialis, Genital herpes, HSV-2, Sexually transmitted infection

The study entitled A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections was conducted by a team of researchers from the U.S. and Germany and was published today in Science Translational Medicine .

Key Points: 
  • The study entitled A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections was conducted by a team of researchers from the U.S. and Germany and was published today in Science Translational Medicine .
  • IM-250 is devoid of off-target activity observed with other anti-HSV drugs and of potential metabolites of previous drug candidates targeting helicase-primase.
  • At least 50 % of the population is infected with Herpes simplex virus type 1 (HSV-1), mostly herpes labialis, whereas approx.
  • 25% of the population is infected withHerpes simplex virus type 2 (HSV-2), mostly genital herpes, a sexually transmitted infection/disease.